Overview

Ashitaba (Angelica keiskei Koidzumi) is a large perennial herb belonging to the Apiaceae (celery/carrot) family, native to the coastal regions of Japan, particularly the Izu and Hachijō Islands. Its Japanese name literally means "tomorrow's leaf," reflecting the plant's remarkable growth vigor — new leaves reportedly sprout within a day of harvesting. Ashitaba has been consumed as a medicinal food in Japan for over 400 years and holds a special place in the folk medicine traditions of Hachijō-jima, a community known for the longevity of its inhabitants. Traditional applications include treatment of digestive disorders, hepatitis, hypertension, diabetes, and skin conditions.

The most pharmacologically distinctive compounds in ashitaba are its prenylated chalcones, particularly xanthoangelol and 4-hydroxyderricin, which are found in the yellow sap of the plant's stems and roots. These chalcones have been extensively studied and demonstrated anti-tumor, anti-inflammatory, anti-obesity, anti-thrombotic, antidiabetic, antihyperlipidemic, and antihypertensive effects in preclinical models. The antidiabetic mechanism involves stimulation of GLUT4-dependent glucose uptake through the LKB1/AMPK signaling pathway. Xanthoangelol and 4-hydroxyderricin also inhibit platelet aggregation, suggesting cardiovascular protective properties. In muscle biology, 4-hydroxyderricin has shown the ability to counteract dexamethasone-induced muscle atrophy through dual mechanisms of reducing protein degradation and stimulating myoblast differentiation via p38 MAPK activation.

In addition to chalcones, ashitaba contains coumarins, flavanones, dietary fiber, and various micronutrients. Accumulated evidence supports its role in addressing components of metabolic syndrome, and research in aging mouse models has demonstrated that ashitaba supplementation prevents age-related thrombotic tendencies and systemic inflammation. Early-stage research has also explored its antimicrobial activity, including effects against multidrug-resistant tuberculosis strains. However, while in vitro evidence is substantial, clinical trials in humans remain limited, and the in vivo efficacy and optimal dosing of ashitaba and its constituents require further investigation.

Mechanism of Action

Chalcone-Mediated Bioactivity

Ashitaba (Angelica keiskei) is distinguished by its unique prenylated chalcones, primarily 4-hydroxyderricin (4-HD) and xanthoangelol (XAG), found in the yellow sap of its stems. These chalcones are responsible for the majority of ashitaba's pharmacological effects, acting as pleiotropic modulators of metabolic and inflammatory signaling (PMID: 22561029).

AMPK Activation & Metabolic Regulation

4-Hydroxyderricin and xanthoangelol potently activate AMP-activated protein kinase (AMPK) in liver, adipose tissue, and skeletal muscle. AMPK activation shifts cellular metabolism toward catabolism: inhibiting acetyl-CoA carboxylase (ACC) to suppress de novo lipogenesis, activating carnitine palmitoyltransferase-1 (CPT-1) for fatty acid beta-oxidation, and enhancing glucose uptake via GLUT4 translocation. This mechanism underlies ashitaba's anti-obesity and insulin-sensitizing effects (PMID: 25123088).

Autophagy Induction via mTOR Suppression

Ashitaba chalcones promote cellular autophagy by inhibiting mTORC1 signaling through AMPK-mediated TSC2 phosphorylation. Enhanced autophagy clears damaged mitochondria (mitophagy), misfolded protein aggregates, and dysfunctional organelles — a mechanism linked to lifespan extension in model organisms. A landmark study demonstrated that 4-HD extended median lifespan in C. elegans, Drosophila, and protected human cardiomyocytes from age-related decline (PMID: 30670597).

Anti-Inflammatory & NF-kB Modulation

Xanthoangelol inhibits NF-kB nuclear translocation by preventing IkB-alpha degradation, suppressing downstream expression of COX-2, iNOS, TNF-alpha, and IL-6. Additionally, ashitaba chalcones inhibit NLRP3 inflammasome assembly, reducing caspase-1 activation and IL-1beta maturation (PMID: 27173433).

Nrf2-Mediated Antioxidant Response

Ashitaba chalcones activate the Keap1-Nrf2-ARE pathway, upregulating phase II detoxification enzymes including heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutathione S-transferases.

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Mild gastrointestinal discomfort including nausea, bloating, and loose stools, particularly with concentrated extract forms or higher doses.
• Photosensitivity: Ashitaba contains furanocoumarins (psoralen derivatives) that can increase skin sensitivity to ultraviolet radiation, potentially leading to phototoxic dermatitis or sunburn with lower UV exposure.
• Allergic contact dermatitis from handling the fresh plant, particularly the sap, which contains bioactive chalcones and coumarins.
• Mild headache and dizziness reported occasionally with oral supplementation.

Contraindications

• Known allergy to Apiaceae (Umbelliferae) family plants, which includes celery, parsley, carrots, fennel, and angelica. Cross-reactivity is possible due to shared allergenic proteins and furanocoumarins.
• Photosensitivity disorders or concurrent phototherapy (PUVA therapy): The furanocoumarin content may cause severe phototoxic reactions.
• Bleeding disorders: Ashitaba chalcones (4-hydroxyderricin, xanthoangelol) have demonstrated antiplatelet and anticoagulant properties in preclinical studies.
• Scheduled surgery: Discontinue at least 2 weeks prior due to potential anticoagulant effects.

Drug Interactions

• Anticoagulants (warfarin, heparin) and antiplatelet agents (aspirin, clopidogrel): Additive bleeding risk due to the antiplatelet properties of ashitaba chalcones.
• Photosensitizing medications (tetracyclines, fluoroquinolones, thiazide diuretics, amiodarone): Concurrent use with ashitaba may compound phototoxicity risk.
• Cytochrome P450 substrates: Preliminary in vitro data suggests ashitaba compounds may inhibit CYP1A2 and CYP3A4, though clinical significance is undetermined. Monitor medications with narrow therapeutic indices metabolized by these enzymes.
• Antidiabetic medications: Some evidence of hypoglycemic activity; monitor blood glucose when combining with insulin or oral hypoglycemics.
• Antihypertensive agents: Ashitaba has demonstrated mild vasodilatory effects; additive hypotension is possible.

Special Populations

• Pregnancy and lactation: Insufficient safety data. The presence of furanocoumarins, which are known teratogens in some animal models, warrants avoidance during pregnancy.
• Pediatric use: No clinical data available; not recommended for children.
• Hepatic impairment: While ashitaba chalcones have shown hepatoprotective properties in some models, patients with active liver disease should use with caution.

Monitoring

• Skin examination for phototoxic reactions, especially during summer months or with UV exposure.
• Coagulation parameters (INR, PT) if used with anticoagulant therapy.
• Blood glucose levels in diabetic patients.
• Liver function tests with prolonged use of concentrated extracts.

Pharmacokinetic Profile